Roivant Sciences Ltd. (NASDAQ: ROIV)

$29.46 ▲ +0.50 (+1.73%)

As of May 12, 2026 12:11 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001635088

Market Cap 19.92 Bn

P/E -32.48

P/S 3,470.34

Div. Yield 0.00

ROIC (Qtr) -0.27

Add ratio to table...

About

Roivant Sciences Ltd is a biopharmaceutical company that accelerates the development and commercialization of medicines that address significant unmet medical need. Its pipeline includes brepocitinib a small molecule inhibitor of TYK2 and JAK1 for dermatomyositis noninfectious uveitis and cutaneous sarcoidosis IMVT 1402 and batoclimab which are monoclonal antibodies targeting the neonatal Fc receptor and mosliciguat an inhaled soluble guanylate cyclase activator for pulmonary hypertension associated with interstitial lung disease. The company creates...

Roivant Sciences Ltd is a biopharmaceutical company that accelerates the development and commercialization of medicines that address significant unmet medical need. Its pipeline includes brepocitinib a small molecule inhibitor of TYK2 and JAK1 for dermatomyositis noninfectious uveitis and cutaneous sarcoidosis IMVT 1402 and batoclimab which are monoclonal antibodies targeting the neonatal Fc receptor and mosliciguat an inhaled soluble guanylate cyclase activator for pulmonary hypertension associated with interstitial lung disease. The company creates focused subsidiaries called Vants to develop each candidate allowing dedicated teams to operate with entrepreneurial independence while benefiting from centralized support. Beyond drug development Roivant incubates early stage companies and health technology startups that complement its core biopharma activities. Since its founding Roivant has secured eight FDA approvals and completed twelve large registrational Phase 3 studies most of which have yielded positive data demonstrating its ability to bring therapies to market. This track record reinforces its reputation as a nimble innovator in the competitive biopharma landscape.

Roivant generates revenue principally through licensing agreements that provide upfront payments milestone payments and royalties on net sales of its product candidates. For example its agreement with Pfizer grants Priovant rights to brepocitinib and obligates Pfizer to pay milestone and royalty payments upon achievement of sales thresholds. Similarly the HanAll agreement provides Immunovant with exclusive rights to batoclimab and IMVT 1402 and includes potential milestone payments up to four hundred twenty million dollars and tiered royalties on net sales. The Bayer partnership supplies Pulmovant with worldwide rights to mosliciguat and entails upfront and milestone payments amounting to two hundred eighty million dollars plus high single digit royalties. The Arbutus cross license gives Genevant access to lipid nanoparticle and GalNAc technologies and requires Genevant to pay low single digit royalties on sales of covered products. Roivant also realized proceeds from the divestment of its Dermavant business to Organon which included an upfront cash payment of one hundred seventy five million dollars a milestone payment of seventy five million dollars upon FDA approval of VTAMA and potential future royalties and milestone payments up to nine hundred fifty million dollars. Additionally the company earns research funding and milestone payments from collaborations with partners such as Novo Nordisk BioNTech Takeda and others that utilize its nucleic acid delivery platforms. These streams collectively fund the advancement of its internal pipeline and support the Vant operating model.

The company operates through the following segments: Priovant Immunovant Pulmovant and Genevant.
Each segment is responsible for the research development and commercialization of its respective product candidates or technology platforms.

• Priovant develops brepocitinib an oral small molecule inhibitor of TYK2 and JAK1 that modulates cytokine signaling involved in dermatomyositis noninfectious uveitis cutaneous sarcoidosis and other immune mediated diseases with the goal of reducing inflammation and preserving tissue function.

• Immunovant advances IMVT 1402 and batoclimab which are fully human monoclonal antibodies that bind the neonatal Fc receptor to lower pathogenic IgG levels thereby ameliorating autoimmune pathology in conditions such as Graves disease rheumatoid arthritis myasthenia gravis chronic inflammatory demyelinating polyneuropathy and cutaneous lupus erythematosus.

• Pulmovant develops mosliciguat an inhaled soluble guanylate cyclase activator that delivers therapeutic concentrations directly to the lungs to reduce pulmonary vascular resistance and improve exercise capacity in patients with pulmonary hypertension associated with interstitial lung disease while also being evaluated for broader cardiopulmonary applications.

• Genevant provides lipid nanoparticle and ligand conjugate delivery platforms that enable partners to formulate nucleic acid therapeutics while retaining intellectual property rights and earning royalties milestone payments and profit sharing from successful collaborations with companies such as Novo Nordisk BioNTech Takeda Korro Bio Repair Biotechnologies Editas Medicine Epitopea and Mammoth Biotechnologies.

Roivant occupies a niche among biopharma firms by employing a Vant structure that grants operational independence to each program while centralizing capital allocation and support functions. This model allows the company to move quickly on promising assets and to avoid the bureaucratic delays often seen in larger pharmaceutical companies. Competitors include established biotech companies that rely on a single integrated development approach and large pharma firms that acquire late stage assets. Roivant differentiates itself through its ability to in license early stage candidates its track record of delivering multiple FDA approvals and its proprietary technology platforms in nucleic acid delivery and inhaled therapies. The company’s diversified pipeline across autoimmune pulmonary hypertension and gene therapy areas reduces reliance on any single product and spreads risk across multiple therapeutic areas. The firm’s ownership stakes in its Vants align incentives with management teams and provide upside potential when programs succeed while preserving flexibility to partner or divest non core assets. This combination of financial discipline entrepreneurial agility and proprietary know how gives Roivant a competitive edge in the search for transformative medicines.

Roivant’s customers include patients physicians hospitals and health systems that ultimately use its approved medicines as well as corporate partners such as Organon Pfizer HanAll Bayer Arbutus Samsung Biologics Novo Nordisk BioNTech Takeda Korro Bio Repair Biotechnologies Editas Medicine Epitopea and Mammoth Biotechnologies which license its technologies or collaborate on drug development. These relationships generate the milestone payments royalties and sales that drive the company’s revenue and provide market validation for its pipeline candidates.

Investment thesis

Bull case

The company’s capital structure remains an attractive catalyst: a $4.4 billion cash reserve with no debt allows Roivant to fund the clinical development of its flagship pipeline without resorting to expensive financing. This cash base is strategically earmarked for bringing brepocitinib to profitability, while the ongoing $500 million share‑repurchase program signals confidence in intrinsic value and provides a disciplined return to shareholders. The combination of robust liquidity and the absence of leverage offers a cushion against regulatory setbacks, positioning the firm to weather the inevitable uncertainties that accompany late‑stage drug development. {bullet} Brepocitinib’s Phase III VALOR data represent a potentially paradigm‑shifting moment in dermatomyositis (DM) therapeutics, a disease that currently offers limited, largely steroid‑centric options. The trial achieved statistically significant outcomes across all primary and secondary endpoints, with a clear dose‑response that identifies the 30 mg daily dose as optimal. The magnitude of clinical benefit, including rapid, deep, and broad responses in both muscle and skin, directly addresses the unmet need for oral disease‑modifying agents in DM, potentially positioning brepocitinib as the first truly novel oral therapeutic in the field. This unique mechanism of action and favorable efficacy profile could translate into a sizable market capture once regulatory approval is obtained. {bullet} The batoclimab data in Graves’ disease add a complementary catalyst by demonstrating sustained remission and substantial steroid sparing in a refractory patient cohort. Out of 25 enrolled patients, 68 % maintained remission after 48 weeks off drug, and more than half were able to discontinue anti‑thyroid medications entirely, with 75 % remaining on the lowest possible dose. The durable reduction in TRAb and IgG levels underscores a mechanistic advantage that could translate into long‑term disease control, offering a disease‑modifying option where current therapies are largely palliative. Early engagement with clinicians and positive KOL feedback suggest a strong launch potential once the program progresses through regulatory review. {bullet} Roivant’s pipeline breadth – 11 potentially registrational trials across indications such as DM, NIU, Graves’, MG, RA, Sjögren’s, and CIDP – establishes a diversified platform that can deliver incremental revenue streams as approvals accumulate. Early IMVT‑1402 data showing deep IgG suppression in multiple autoimmune settings signal that the FcRn mechanism may have broad applicability, potentially creating first‑ or best‑in‑class opportunities across a spectrum of orphan and non‑orphan markets. The staggered timing of data readouts, with key NIU and NIU‑based approvals anticipated in 2027, creates a predictable product launch calendar that can be leveraged for strategic partnerships and commercial ramp‑up. {bullet} The company’s legal posture also provides a strategic edge: a favorable Markman ruling in the Pfizer LNP litigation reduces the risk of costly infringement judgments, while the upcoming Moderna trial in March 2026 offers the possibility of a favorable outcome that could further protect Roivant’s intellectual property. These developments reduce legal exposure and preserve the company’s ability to invest in its pipeline rather than allocate capital to litigation defense. In the event of a favorable ruling, the company would secure a stronger IP moat around its lipid‑nanoparticle delivery technology, a core component of several pipeline assets. {bullet} The December 11 Investor Day is slated to provide additional catalysts, with expectations of data from the NIU, TED, and Pulmovant programs. Anticipated readouts in the second half of next year will help refine commercial strategy and potentially unlock valuation upside, especially if the data demonstrate the expected translational benefit seen in Phase II. The event will also be an opportunity to clarify regulatory timelines and commercialization plans for brepocitinib and batoclimab, further reducing uncertainty for investors and strengthening the case for future capital allocation.

The company’s capital structure remains an attractive catalyst: a $4.4 billion cash reserve with no debt allows Roivant to fund the clinical development of its flagship pipeline without resorting to expensive financing. This cash base is strategically earmarked for bringing brepocitinib to profitability, while the ongoing $500 million share‑repurchase program signals confidence in intrinsic value and provides a disciplined return to shareholders. The combination of robust liquidity and the absence of leverage offers a cushion against regulatory setbacks, positioning the firm to weather the inevitable uncertainties that accompany late‑stage drug development. {bullet} Brepocitinib’s Phase III VALOR data represent a potentially paradigm‑shifting moment in dermatomyositis (DM) therapeutics, a disease that currently offers limited, largely steroid‑centric options. The trial achieved statistically significant outcomes across all primary and secondary endpoints, with a clear dose‑response that identifies the 30 mg daily dose as optimal. The magnitude of clinical benefit, including rapid, deep, and broad responses in both muscle and skin, directly addresses the unmet need for oral disease‑modifying agents in DM, potentially positioning brepocitinib as the first truly novel oral therapeutic in the field. This unique mechanism of action and favorable efficacy profile could translate into a sizable market capture once regulatory approval is obtained. {bullet} The batoclimab data in Graves’ disease add a complementary catalyst by demonstrating sustained remission and substantial steroid sparing in a refractory patient cohort. Out of 25 enrolled patients, 68 % maintained remission after 48 weeks off drug, and more than half were able to discontinue anti‑thyroid medications entirely, with 75 % remaining on the lowest possible dose. The durable reduction in TRAb and IgG levels underscores a mechanistic advantage that could translate into long‑term disease control, offering a disease‑modifying option where current therapies are largely palliative. Early engagement with clinicians and positive KOL feedback suggest a strong launch potential once the program progresses through regulatory review. {bullet} Roivant’s pipeline breadth – 11 potentially registrational trials across indications such as DM, NIU, Graves’, MG, RA, Sjögren’s, and CIDP – establishes a diversified platform that can deliver incremental revenue streams as approvals accumulate. Early IMVT‑1402 data showing deep IgG suppression in multiple autoimmune settings signal that the FcRn mechanism may have broad applicability, potentially creating first‑ or best‑in‑class opportunities across a spectrum of orphan and non‑orphan markets. The staggered timing of data readouts, with key NIU and NIU‑based approvals anticipated in 2027, creates a predictable product launch calendar that can be leveraged for strategic partnerships and commercial ramp‑up. {bullet} The company’s legal posture also provides a strategic edge: a favorable Markman ruling in the Pfizer LNP litigation reduces the risk of costly infringement judgments, while the upcoming Moderna trial in March 2026 offers the possibility of a favorable outcome that could further protect Roivant’s intellectual property. These developments reduce legal exposure and preserve the company’s ability to invest in its pipeline rather than allocate capital to litigation defense. In the event of a favorable ruling, the company would secure a stronger IP moat around its lipid‑nanoparticle delivery technology, a core component of several pipeline assets. {bullet} The December 11 Investor Day is slated to provide additional catalysts, with expectations of data from the NIU, TED, and Pulmovant programs. Anticipated readouts in the second half of next year will help refine commercial strategy and potentially unlock valuation upside, especially if the data demonstrate the expected translational benefit seen in Phase II. The event will also be an opportunity to clarify regulatory timelines and commercialization plans for brepocitinib and batoclimab, further reducing uncertainty for investors and strengthening the case for future capital allocation.

Bear case

Despite the impressive clinical data, the regulatory pathway for brepocitinib remains uncertain; the NDA filing is still in draft, and the FDA’s review timeline is unknown, creating a risk that approval could be delayed or that the agency might request additional studies. Competing oral therapies and biologics in the DM space could also erode the first‑mover advantage, especially if alternative agents with more favorable safety profiles enter the market. A protracted approval process would extend the burn rate and delay the time to revenue generation, undermining the company’s growth narrative. {bullet} The Graves’ disease program, while promising, operates in a rapidly evolving competitive landscape that includes several FcRn and non‑FcRn candidates targeting both Graves’ disease and thyroid eye disease (TED). The company’s decision to hold back the TED top‑line data until the second study concludes reflects a cautious approach but also introduces uncertainty around the commercial trajectory of batoclimab. If competitors deliver faster or more compelling data, Roivant may face pricing pressure or market share erosion, especially if the therapeutic window for Graves’ disease is narrower than anticipated. {bullet} Litigation risks continue to loom large, as the pending trials against Moderna and the ongoing discovery in the Pfizer case could culminate in adverse judgments or costly settlements. An unfavorable outcome could not only lead to direct financial liabilities but also distract management from clinical development priorities, reducing focus on accelerating the pipeline. Even a neutral ruling may trigger costly appeals or additional defenses, thereby straining the company’s resources and potentially delaying product launch timelines. {bullet} While the $4.4 billion cash position is solid, the company’s aggressive share repurchase program and extensive pipeline development impose a significant cash burn that could constrain future flexibility. The absence of debt does not eliminate the risk of liquidity depletion if regulatory approvals are delayed or if a critical asset fails to secure market acceptance. Furthermore, future equity issuances or debt financing may be required to sustain the heavy development spend, potentially diluting existing shareholders and impacting valuation multiples. {bullet} The pipeline’s breadth is simultaneously a strength and a vulnerability: many of the 11 registrational programs are still in Phase II or early Phase III, and only brepocitinib and batoclimab have produced robust data. Indications such as NIU, MG, RA, and Sjögren’s lack mature data sets, leaving their commercial prospects uncertain. Should any of these programs encounter late‑stage failure, the company’s valuation could suffer, as the remaining assets would represent a smaller portion of the total portfolio value. {bullet} Several key questions during the Q&A were answered with strategic ambiguity, notably the CEO’s lack of specific timelines for FDA decisions, the sequencing of batoclimab across Graves’ disease and TED, and the exact impact of the favorable Markman ruling on the company’s overall IP strategy. This evasiveness may signal that the company’s commercial strategy is not fully crystallized, raising concerns about the speed and efficiency with which it can bring products to market. Investors may interpret the lack of concrete milestones as a risk factor for underperformance relative to market expectations.

Despite the impressive clinical data, the regulatory pathway for brepocitinib remains uncertain; the NDA filing is still in draft, and the FDA’s review timeline is unknown, creating a risk that approval could be delayed or that the agency might request additional studies. Competing oral therapies and biologics in the DM space could also erode the first‑mover advantage, especially if alternative agents with more favorable safety profiles enter the market. A protracted approval process would extend the burn rate and delay the time to revenue generation, undermining the company’s growth narrative. {bullet} The Graves’ disease program, while promising, operates in a rapidly evolving competitive landscape that includes several FcRn and non‑FcRn candidates targeting both Graves’ disease and thyroid eye disease (TED). The company’s decision to hold back the TED top‑line data until the second study concludes reflects a cautious approach but also introduces uncertainty around the commercial trajectory of batoclimab. If competitors deliver faster or more compelling data, Roivant may face pricing pressure or market share erosion, especially if the therapeutic window for Graves’ disease is narrower than anticipated. {bullet} Litigation risks continue to loom large, as the pending trials against Moderna and the ongoing discovery in the Pfizer case could culminate in adverse judgments or costly settlements. An unfavorable outcome could not only lead to direct financial liabilities but also distract management from clinical development priorities, reducing focus on accelerating the pipeline. Even a neutral ruling may trigger costly appeals or additional defenses, thereby straining the company’s resources and potentially delaying product launch timelines. {bullet} While the $4.4 billion cash position is solid, the company’s aggressive share repurchase program and extensive pipeline development impose a significant cash burn that could constrain future flexibility. The absence of debt does not eliminate the risk of liquidity depletion if regulatory approvals are delayed or if a critical asset fails to secure market acceptance. Furthermore, future equity issuances or debt financing may be required to sustain the heavy development spend, potentially diluting existing shareholders and impacting valuation multiples. {bullet} The pipeline’s breadth is simultaneously a strength and a vulnerability: many of the 11 registrational programs are still in Phase II or early Phase III, and only brepocitinib and batoclimab have produced robust data. Indications such as NIU, MG, RA, and Sjögren’s lack mature data sets, leaving their commercial prospects uncertain. Should any of these programs encounter late‑stage failure, the company’s valuation could suffer, as the remaining assets would represent a smaller portion of the total portfolio value. {bullet} Several key questions during the Q&A were answered with strategic ambiguity, notably the CEO’s lack of specific timelines for FDA decisions, the sequencing of batoclimab across Graves’ disease and TED, and the exact impact of the favorable Markman ruling on the company’s overall IP strategy. This evasiveness may signal that the company’s commercial strategy is not fully crystallized, raising concerns about the speed and efficiency with which it can bring products to market. Investors may interpret the lack of concrete milestones as a risk factor for underperformance relative to market expectations.

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools